Search Results - chemotherapy%2fimmunotherapy

3 Results

Sort By:

M4N and Temozolomide Combination Therapy for Glioblastoma multiforme (GBM)

Unmet NeedGlioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults and remains one of the most aggressive types of malignancies. The mainstay of GBM treatment is surgery, radiation and adjuvant chemotherapy using temozolomide (TMZ). While treatment options have incrementally improved, survival rates remains dismal. Only...

Published: 5/9/2024 | Inventor(s): Ru Chih Huang, Jong ho Chun, Yu-Ling Lin, Yu-Chuan Liang, Kuang-Wen Liao, Tiffany Jackson, David Mold, Chien-Hsien Lai

Keywords(s): Agonists/Promoters, Brain Cancer, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Glioblastoma, Glioma, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Brain Cancer

Use of Combination Retinoic Acid and dsRNA Products for Skin Rejuvenation

Unmet NeedGlobally, the anti-aging cosmetic treatment market is projected to grow to $57.5B dollars in 2020. Currently, one of the leading the leading topical ingredients in anti-aging creams for wrinkle reduction is retinoids, which are derivatives of vitamin A. Retinoic acid, the active metabolite of retinoids, has been shown to help repair sun damaged...

Published: 5/9/2024 | Inventor(s): Luis Garza, Dongwon Kim

Keywords(s): Biologics, Chemotherapy/Immunotherapy, Combination, Disease Indication, Nucleic Acid, Skin Disorders, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Wound Healing

Category(s): Technology Classifications > Therapeutic Modalities

Targeted delivery of antigenic CTL peptide to tumor loci by Annexin V renders tumor cells susceptible to adaptive CD8+ cell immunity

Antigen-specific immunotherapy represents a promising methodology to control tumors because it can stimulate the immune system to specifically target and eliminate tumor cells. To overcome the challenge of immune tolerance, which is common to immunotherapy, we generated a novel chimeric protein to selectively coat tumor cells with a foreign immunogenic...

Published: 5/9/2024 | Inventor(s): Chien-Fu Hung, T.c. Wu

Keywords(s): Antigens, Biologics, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities